NCT04044079View on ClinicalTrials.gov

Vaginal Dinoprostone Versus Vaginal Misoprostol Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients

PHASE4CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

August 20, 2019

Primary Completion Date

January 10, 2020

Study Completion Date

February 10, 2020

Conditions

Office Hysteroscopy

Interventions

DRUG

Dinoprostone

1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.

DRUG

Misoprostol

Misoprostol (200µg) will be administered vaginally 12 hours before office hysteroscopy.

DRUG

Placebo

one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.

Trial Locations (1)

11231

Ahmed Samy, Giza

All Listed Sponsors

lead

Cairo University

OTHER

NCT04044079 - Vaginal Dinoprostone Versus Vaginal Misoprostol Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients | Biotech Hunter | Biotech Hunter